38.6c New Delhi, India, Wednesday, April 17, 2024

Biocon Partner Mylan Gets Favorable Ruling in Patent Case on Insulin Glargine (Used in Diabetes)

By Parth Thummar      02 June, 2020 01:14 PM      0 Comments
Biocon Mylan Patent Case Insulin Glargine

In a boost to Biocon's Insulin glargine application in the US, partner Mylan has got a favorable ruling from the US Patent and Trademark Appeal Board (US PTAB) in its case against Sanofi. Sanofi is the innovator of insulin glargine.

The US Patent Office has ruled in favor of Mylan for a total of four device patents on Sanofi’s Lantus SoloSTAR. Lantus SoloSTAR is the disposable injection pen version of the drug. The other version by Sanofi Lantus is sold in the form of vials.

Biocon and Mylan have one application pending for insulin glargine, which is the biosimilar version of Sanofi’s Lantus with the US Drug Regulator. Biocon’s version of insulin glargine is branded as Semglee. The drug insulin glargine is a long-acting insulin used to manage both Type 1 and Type 2 diabetes.

Biocon and Mylan are currently awaiting the US drug regulator’s final nod for insulin glargine. Biocon is expecting to launch the drug in the US markets by this year. According to the CEO and Managing Director of Biocon Biologics, Dr. Christiane Hamacher, the ruling ‘further clears the path’ for the launch of insulin glargine in the US.

According to analysts, the market size of insulin glargine is projected to be over $2 billion for the US. Currently, this market size is split between two companies Sanofi and Eli Lily. Lily’s version of the drug was available in most countries around 5 years ago and is sold under the brand names Basaglar and Abasaglar.

One of the key challenges that Biocon faces on insulin glargine is the lack of an interchangeable status. That means a doctor needs to specifically prescribe Semglee and it cannot be sold as a replacement for Lantus or Basaglar. That means Mylan is probably going to have to promote the drug which could even become unviable later.

Share this article:

Leave a feedback about this

Trending Judiciary
Baba Ramdev, Acharya Balkrishna offer to make public apology in SC for misleading advertisements

Baba Ramdev and Acharya Balkrishna offer public apology in SC for misleading ads, court deliberates acceptance.

16 April, 2024 01:57 PM
Trending Judiciary
Non-tear of the hymen is of no consequence in cases of penetrative sexual assault: Guwahati HC in POCSO case [Read Judgment]

Hymen tear or genital injuries are not a sine qua non to prove penetrative sexual assault, the Guwahati High Court has held in a case under the POCSO Act, 2012.

16 April, 2024 05:06 PM


Trending Business
SC sets aside judgment upholding arbitral award against DMRC [Read Judgment]

Supreme Court overturns arbitral award favoring Reliance Infrastructure subsidiary against DMRC, citing grave miscarriage of justice.

11 April, 2024 11:43 AM
Trending Political NEWS
Delhi HC rejects third plea for Arvind Kejriwal's removal as Delhi CM, blasts petitioner for abuse of judicial process [Read Judgment]

Delhi High Court dismisses the third PIL plea before it seeking Aam Aadmi Party leader Arvind Kejriwal’s removal as Chief Minister of Delhi, imposes Rs. 50,000 cost on petitioner.

11 April, 2024 03:29 PM
Trending Judiciary
Use of social media to interfere with administration of justice needs serious consideration: SC [Read Judgment]

Supreme Court warns against social media misuse in legal matters, cautions against prejudicial posts interfering with justice.

11 April, 2024 05:44 PM
Trending Legal Insiders
Two-day conference on April 13-14 on Technology and Dialogue between SC and Singapore

Explore AI's role in law at the India-Singapore Supreme Court conference on technology, enhancing judicial processes and access to justice, April 13-14, 2024.

12 April, 2024 06:16 PM


Join Group

Signup for Our Newsletter

Get Exclusive access to members only content by email